Molecularly targeted drugs for metastatic colorectal cancer

Ying-dong Cheng
Hua Yang
Guo-qing Chen
Zhi-cao Zhang
Department of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, People’s Republic of China

Abstract: The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a substantial improvement in the overall survival rate. These drugs are capable of specifically targeting the inherent abnormal pathways in cancer cells, which are potentially less toxic than traditional nonselective chemotherapeutics. In this review, the recent clinical information about molecularly targeted therapy for mCRC is summarized, with specific focus on several of the US Food and Drug Administration-approved molecularly targeted drugs for the treatment of mCRC in the clinic. Progression-free and overall survival in patients with mCRC was improved greatly by the addition of bevacizumab and/or cetuximab to standard chemotherapy, in either first- or second-line treatment. Aflibercept has been used in combination with folinic acid (leucovorin)–fluorouracil–irinotecan (FOLFIRI) chemotherapy in mCRC patients and among patients with mCRC with wild-type KRAS, the outcomes were significantly improved by panitumumab in combination with folinic acid (leucovorin)–fluorouracil–oxaliplatin (FOLFOX) or FOLFIRI. Because of the new preliminary studies, it has been recommended that regorafenib be used with FOLFOX or FOLFIRI as first- or second-line treatment of mCRC chemotherapy. In summary, an era of new opportunities has been opened for treatment of mCRC and/or other malignancies, resulting from the discovery of new selective targeting drugs.

Keywords: metastatic colorectal cancer (mCRC), antiangiogenic drug, bevacizumab, aflibercept, regorafenib, cetuximab, panitumumab, clinical trial, molecularly targeted therapy

Introduction
Colorectal cancer (CRC) is one of the most malignant types of cancers. In the US and Europe, CRC is the second most frequent cancer that leads to death, which ranks below only lung cancer.1 The incidence of CRC in the People’s Republic of China has been reported to increase annually and will continue to rise in the next few years.2 Currently, there are approximately 1.25 million patients diagnosed with CRC, and more than 600,000 patients will die from this disease every year.3 Metastases develop in at least 50% of CRC patients, and most of these patients have unresectable tumors.4 When tumor lesions are not fully resectable or become metastatic, the first treatment option is chemotherapy. Since the 1990s, fluorouracil (5FU)-based chemotherapy has improved the survival rate of patients with metastatic CRC (mCRC) to an overall survival (OS) of 12 months, and the addition of oxaliplatin and irinotecan increased the OS to approximately 18 months.5–8 The addition of molecularly targeted drugs, such as bevacizumab, led to a substantial jump in OS, which approached 30 months in some studies.9 In 2007, monoclonal antibody (mAb) therapy was first
recommended for mCRC.\textsuperscript{10,11} According to the European and US guidelines, the combination of chemotherapy and a mAb is recommended for the first-line treatment of mCRC, and the second-line treatment depends on the first-line regimen used. For patients with chemoresistant mCRC with wild-type KRAS, monotherapy with cetuximab or panitumumab is recommended.\textsuperscript{12} In addition, regorafenib was recently approved by the US Food and Drug Administration (FDA) for the treatment of mCRC patients who have been treated with chemotherapy previously, which is used in combination with an anti-vascular endothelial growth factor (VEGF) therapy, or with an anti-epidermal growth factor receptor (EGFR) therapy in case of wild-type KRAS.\textsuperscript{13} In recent years, significant advances have been made in the integration of targeted therapies in the treatment of mCRC and a plethora of new data have been published shedding light on the efficacy of targeted drugs in treatment of mCRC. However, these data have sometimes been inconsistent, resulting in a challenging environment in which physicians are required to make treatment choices. This review focuses on several FDA-approved molecularly targeted drugs that are being used regularly in the treatment of mCRC.

**Bevacizumab, an angiogenesis inhibitor**

Bevacizumab (Avastin; Genentech/Roche, San Francisco, CA, USA) is a humanized mAb that inhibits the growth of new blood vessels. As the first clinically available inhibitor of angiogenesis in the US, bevacizumab has been licensed to treat various cancers, including breast (outside the US),\textsuperscript{14-16} glioblastoma (US only),\textsuperscript{17,18} lung,\textsuperscript{19,20} kidney,\textsuperscript{21,22} ovarian\textsuperscript{23-25} and CRC.\textsuperscript{26-28} Mechanically, bevacizumab inhibits VEGF-A,\textsuperscript{29} a chemical signal that mediates angiogenesis, which is required for the development of cancer.\textsuperscript{30,31} Figure 1 shows how the VEGF-A signaling pathway is linked to its main biological functions. VEGF-A can bind VEGF receptor (VEGFR)-2 dimer. Neuruplin (NRP)-1 and -2 are co-receptors that stabilize the VEGFR-2 dimer.\textsuperscript{32} Upon ligand binding to VEGFR-2 dimer, several signaling pathways can be activated, affecting diverse biological processes in endothelial and cancer cells. Anti-VEGF-A mAb, such as bevacizumab, can bind VEGF-A and block its function. While it has been clearly demonstrated that bevacizumab has antitumor efficacy in various cancers, especially in combination with conventional chemotherapy, its exact mechanism of action remains not fully understood. Continued VEGF-A inhibition with bevacizumab can play an important role in improving the overall success of therapy for patients who have mCRC.\textsuperscript{9} However, many patients inevitably relapsed due to the newly acquired resistance, even though the progression-free survival (PFS) was statistically increased.\textsuperscript{33,34}

When combined with 5FU-based chemotherapy, bevacizumab was found to significantly prolong the OS and PFS of patients with mCRC. For this reason, bevacizumab was first approved in 2004 for the combined use with standard chemotherapy for the treatment of mCRC.\textsuperscript{35,36} In 2005, the European Medicines Agency also approved bevacizumab in combination with irinotecan, a chemotherapeutic drug that prevents DNA from unwinding by inhibition of topoisomerase 1 for first-line treatment of mCRC.\textsuperscript{37} Bevacizumab was further approved for mCRC in combination with standard fluoropyrimidine-based chemotherapy after its benefits were demonstrated by randomized studies.\textsuperscript{38,39} More recently, on January 23, 2013, bevacizumab was approved to be used in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for the treatment of mCRC.\textsuperscript{40} The approval allows patients who received the first-line treatment with bevacizumab plus an irinotecan- or oxaliplatin-containing chemotherapy to continue to receive bevacizumab plus a different irinotecan- or oxaliplatin-containing chemotherapy as the second-line treatment after their cancer worsens.\textsuperscript{40}

The use of bevacizumab with standard chemotherapy has improved PFS and OS for the treatment of mCRC in both first- and second-line treatment; however, the clinical significance of maintenance bevacizumab remains controversial. In a Phase III trial to compare the efficacy and safety of bevacizumab alone with bevacizumab and capcitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with mCRC, Diaz-Rubio et al did not find statistically significant differences in the median PFS or OS times between bevacizumab-treated versus XELOX plus bevacizumab-treated patients.\textsuperscript{41} The results of a recent retrospective study indicate that the maintenance therapy with bevacizumab is a safe and valuable option in mCRC patients, especially in those who achieve an objective response after first-line chemotherapy.\textsuperscript{42} In addition, two reports from the 2013 American Society of Clinical Oncology (ASCO) annual meeting support the use of bevacizumab in maintenance treatment of mCRC.\textsuperscript{43,44}

In summary, PFS and OS have been significantly improved by the addition of bevacizumab to standard chemotherapy in patients with mCRC in both first- and second-line treatment. Still, the role of bevacizumab as maintenance treatment of mCRC needs further studies.
Aflibercept, a fusion protein

Aflibercept (ZALTRAP; co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA) is a fusion protein for the treatment of wet macular degeneration and mCRC. The mechanism of aflibercept action is to target VEGF-A, VEGF-B, and placental growth factor (PIGF) by blocking angiogenesis. It also prevents the activation of VEGFR-1 and VEGFR-2 by these ligands. As a member of the VEGF family, PIGF specifically binds to VEGFR-1 and enhances VEGF-A expression, which plays an important role in angiogenesis. PIGF expression is also upregulated by anti-VEGF therapy in cancer patients, indicating that PIGF may also play a role in the resistance to anti-VEGF treatment. In addition, aflibercept was shown to inhibit tumor proliferation, angiogenesis, and metastases in tumor-bearing mouse model.

On August 3, 2012, aflibercept was approved by the FDA for patients who were previously treated with mCRC. The approval stipulates that aflibercept can be used in combination with folinic acid (leucovorin)–5FU–irinotecan (FOLFIRI) chemotherapy for mCRC patients whose cancer has progressed or demonstrated resistance to oxaliplatin (Eloxatin; Sanofi-Aventis)-based chemotherapy. The benefit of aflibercept in combination with FOLFIRI was confirmed in the Phase III VELOUR trial. In this study, aflibercept or placebo combined with FOLFIRI was administered to
patients with mCRC at 4 mg/kg intravenously every 2 weeks. The results demonstrate that the aflibercept-containing group had better PFS (6.9 versus 4.67 months; hazard ratio [HR] 0.758; \( P < 0.0001 \)) and OS (13.5 versus 12.06 months; HR 0.817; \( P = 0.0032 \)) compared to the control group. In the aflibercept arm, the overall response rate was 19.8\%, whereas in the placebo arm, the overall response rate was 11.1\% \( (P = 0.0001) \).

It seems that the benefit achieved by aflibercept and bevacizumab are comparable in second-line settings. As shown in a clinical trial, a median OS improvement of 1.4 months (HR 0.81; 95\% confidence interval [CI]: 0.69–0.94; \( P = 0.0062 \)) was achieved when bevacizumab was continued in the second-line while switching the cytotoxic chemotherapy. Meanwhile, in the VELOUR trial, the addition of aflibercept to FOLFIRI resulted in a comparable median OS survival improvement of 1.44 months (HR 0.817; 95.34\% CI: 0.713–0.937; \( P = 0.0032 \)). However, compared to bevacizumab, aflibercept appeared to have a higher frequency of vascular-related adverse events. Therefore, aflibercept is not recommended for routine use in mCRC patients who progress on oxaliplatin-containing treatment.

### Cetuximab, a chimeric monoclonal antibody

Cetuximab (Erbitux), a chimeric (mouse/human) monoclonal antibody, is manufactured and distributed by Bristol-Myers Squibb (New York, NY, USA) and Eli Lilly and Company (Indianapolis, IN, USA). This drug is specific to the EGFR, which is administered by intravenous infusion. Cetuximab is able to induce various proapoptotic factors, such as Bax, leading to the activation of caspases and thus triggering apoptosis. In addition, cetuximab can also recruit immune cells to tumor cells, thereby inducing antibody-dependent cellular cytotoxicity in vivo.

Figure 2 shows the EGFR pathway and its main downstream effectors, PI3K/AKT and KRAS/BRAF/MEK/MEK. Activated AKT and MEK/ERK can induce cancer cell proliferation and invasion. In addition, activated AKT can induce cancer stem cell renewal and differentiation.

**Figure 2** An overview of the EGFR pathway and its main downstream effectors, PI3K/AKT and KRAS/BRAF/MEK/MEK.

**Notes:** Activated AKT and MEK/MEK can induce cancer cell proliferation and invasion. In addition, activated AKT can induce cancer stem cell renewal and differentiation. Anti-EGFR mAbs, such as cetuximab or panitumumab, can bind EGFR and block its function.

**Abbreviations:** EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; CSC, cancer stem cell.
Anti-EGFR mAbs, such as cetuximab, can bind EGFR and block its function.

Initially, cetuximab was used in the palliative treatment of tumor. This drug, either as monotherapy or in combination with chemotherapy and/or radiation, particularly in the settings of mCRC, has shown positive antitumor activity in clinical trials. In 2004, cetuximab was approved to be used for patients with EGFR-expressing mCRC who are refractory to irinotecan-based chemotherapy. Subsequently, there have been several clinical trials supporting the use of cetuximab for the treatment of mCRC. On July 6, 2012, the FDA approved the combination of cetuximab with FOLFIRI as the first-line treatment for patients with mutation-negative (wild-type) K-ras and EGFR-expressing mCRC. Concurrent with this approval, the therascreen KRAS RGQ PCR Kit (QIAGEN Manchester, Ltd) was also approved by the FDA for determining the K-ras mutations. The approval of cetuximab and KRAS mutation kit was based on the results of the CRYSTAL trial and two supportive studies, CA225025 and EMR 62 202-047 (OPUS), which made retrospective analyses of tumor samples from a large number of patients in accordance with K-ras mutation status. The addition of cetuximab to chemotherapy has significantly improved the OS, PFS, and the overall response rates in patients with K-ras wild-type tumors. However, no benefit, or even potential harm, has been observed in patients with K-ras mutant tumors.

The efficacy of down-staging programs in mCRC patients can be improved by the addition of cetuximab to conventional chemotherapy regimens, which may offer patients potential curative resection. However, it is well recognized that both intrinsic and acquired resistance have been developed despite the clinical gains arising from use of cetuximab. Therefore, there remains the need to develop more efficient antibody-based anti-EGFR therapies.

Panitumumab, a fully human monoclonal antibody
Panitumumab (Vectibix; Amgen Inc, Thousand Oaks, CA, USA) specifically blocks the EGFR extracellular domain. As a fully human monoclonal antibody, it can be used as a single drug in patients who are chemotherapy refractory or in different combinations. In either setting, panitumumab has been shown to be well tolerated and efficacious.

Panitumumab was first approved in September 2006 in the US and in 2007 in Europe as a monotherapy for the treatment of mCRC that is EGFR-expressing and refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. However, in patients with KRAS mutations in codons 12 or 13, use of panitumumab is not recommended. Recently, clinical studies have been conducted focusing on the potential benefits of treatment of mCRC with panitumumab in combination with chemotherapy. The results of these studies support that the clinical outcomes of patients with wild-type KRAS are improved by the addition of panitumumab to chemotherapy. In another study, PFS was significantly improved by the addition of panitumumab to first-line folinic acid (leucovorin)–5FU–oxaliplatin (FOLFOX)4, which was 9.6 versus 8.0 months compared with FOLFOX4 alone (HR 0.80; 95% CI: 0.66–0.97; P=0.02). However, addition of panitumumab to FOLFOX4 did not significantly improve the median OS in the patients with wild-type KRAS tumors (23.9 versus 19.7 months compared to FOLFOX4 alone; HR 0.83; 95% CI: 0.67–1.02; P=0.072). In case of failure of initial treatment for mCRC with one prior chemotherapy regimen, the addition of panitumumab to FOLFIRI significantly improves the PFS in the wild-type KRAS subgroup, with 5.9 months for panitumumab–FOLFIRI versus 3.9 months for FOLFIRI alone (HR 0.73; 95% CI: 0.59–0.90; P=0.004). A trend toward increased OS was also observed, although it was not statistically significant. The median OS was improved from 12.5 to 14.5 months, and the response rate increased from 10% to 35% with the addition of panitumumab compared to FOLFIRI alone. However, no difference in efficacy was observed in patients with mutant KRAS. Additional reports also demonstrate that, for patients with wild-type KRAS tumors, the objective response rate, PFS, and OS are numerically improved by panitumumab plus FOLFIRI.

Overall, the results of the above studies support that panitumumab in combination with FOLFOX or FOLFIRI improves the outcomes among patients with mCRC with wild-type KRAS.

Regorafenib, a multikinase inhibitor
As an oral multikinase inhibitor, regorafenib (BAY 73-4506) Stivarga; Bayer AG, Leverkusen, Germany) targets angiogenic, stromal, oncogenic receptor tyrosine kinase (RTK) as well as tumor microenvironment (platelet-derived growth factor receptor [PDGFR] and fibroblast growth factor receptor [FGFR]). Multiple membrane-bound and intra-cellular kinases are inhibited by regorafenib and its active metabolites. Therefore, multiple normal cellular functions and pathologic processes are inhibited, including the RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, Tie2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl pathways.
was further reported that regorafenib is effective in inhibiting angiogenesis, tumorigenesis, and metastasis in a highly aggressive metastatic colon cancer murine model, indicating its potential in the treatment of advanced CRCs.\textsuperscript{87}

On September 27, 2012, the FDA approved regorafenib to be used in combination with an anti-VEGF therapy (or an anti-EGFR therapy, if wild-type KRAS), for the treatment of mCRC that has been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.\textsuperscript{13} In an international, randomized (2:1), double-blind, and placebo-controlled trial (study 14387) conducted in 760 patients with previously treated mCRC, regorafenib treatment resulted in a statistically significant prolongation in OS [HR: 0.77; 95% CI: 0.64–0.94; \( P=0.0102\)], with 6.4 months (95% CI: 5.8–7.3) of median survival time in the regorafenib group versus 5.0 months (95% CI: 4.4–5.8) in the placebo group. A statistically significant improvement in PFS was also demonstrated in patients who were treated with regorafenib [HR 0.49; 95% CI: 0.42–0.58; \( P<0.0001\)]. Specifically, the median PFS in patients receiving regorafenib was 2.0 months (95% CI: 1.9–2.3), whereas, in the placebo group, the median PFS was 1.7 months (95% CI: 1.7–1.8).\textsuperscript{13}

As shown in a recent preliminary study, regorafenib in combination with FOLFOX or FOLFIRI has an acceptable tolerability as first- or second-line treatment of mCRC chemotherapy.\textsuperscript{88} In other tumor types, regorafenib has also shown exciting potential, especially in gastrointestinal stromal tumors.\textsuperscript{86,89}

Conclusion

With the discovery of a plethora of molecular cellular targets, a large number of selective targeting drugs have been generated, and this has opened a new era for cancer therapy. These drugs specifically target the inherent abnormalities of cancer cells, which is potentially less toxic than traditional nonselective cytotoxic drugs. Addition of these drugs, such as bevacizumab and/or cetuximab, to standard chemotherapy has resulted in improved PFS and OS in patients with mCRC, either in first- or second-line treatment. In patients with mCRC that has progressed on or is resistant to oxaliplatin (Eloxatin)-based chemotherapy, aflibercept has been used in combination with FOLFIRI chemotherapy. Among patients with mCRC with wild-type KRAS, the outcomes are improved when panitumumab is added to FOLFOX or FOLFIRI chemotherapy. Regorafenib can be used in combination with FOLFOX or FOLFIRI as first- or second-line treatment of mCRC chemotherapy.

Disclosure

The authors report no conflicts of interest in this work. The authors retained full editorial control over the content of the manuscript and received no compensation from any party for their work.

References


